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Prion diseases are fatal neurodegenerative disorders. Pathology is closely linked to the misfolding of native
cellularPrP
C into thedisease-associated form PrP
Sc that accumulates inthe brain asdiseaseprogresses.Although
treatments haveyet to be developed, strategies aimed at stimulatingthe degradation ofPrP
Sc have shown efﬁca-
cy in experimental models of prion disease. Here, we describe the cellular pathways that mediate PrP
Sc degrada-
tion and review possible targets for therapeutic intervention. This article is part of a Special Issue entitled
‘Neuronal Protein’.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Prion diseases are thought to be caused by the misfolding of native
cellular prion protein (PrP
C)i n t oaβ-sheet rich aggregation prone
form (PrP
Sc). Their pathogenesis is associated with thebuild-up of PrP
Sc
in the brains of affected individuals (Prusiner, 1998). As a result, prion
diseases are included in a group of neurodegenerative disorders termed
the proteinopathies, alongside Alzheimer's disease (AD), Parkinson's
disease(PD)andHuntington'sdisease(HD)(Soto,2003).Theabnormal
protein aggregates which accumulate in these disorders are thought to
result in a toxic gain of function that ultimately leads to cell death and
disease pathogenesis. Debate about the nature of these toxic effects
is ongoing (Lindquist and Kelly, 2011); however, recent evidence
has emerged implicating impaired protein homeostasis (proteostasis)
as a major cause of toxicity common to these disorders (Hetz and
Mollereau, 2014; Lindquist and Kelly, 2011). To function efﬁciently,
cells must maintain protein content (proteome) in an active state. This
presents a signiﬁcant challenge given the inherently unstable nature
of many proteinsunder physiological conditions. Proteostasis is deﬁned
as the balance between the protein degradation and synthesis needed
to remove and replace denatured proteins, respectively. Almost 1400
proteins (~14% of the proteome) regulate proteostasis in mammalian
cells, as part of a tightly co-ordinated proteostasis network (Kim et al.,
2013; Powers et al., 2009).
Protein translation is regulated by a series of initiation and elon-
gation factors. One of the key regulators is eIF2α (Walter and Ron,
2011) which is targeted by a number of signal transduction pathways
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Harding et al., 1999). Phosphorylation of eIF2α inhibits its activity and
suppresses global protein synthesis (Walter and Ron, 2011). This path-
way forms a key arm of the unfolded protein response (UPR), which is
activated during conditions of cellular stress. The UPR has been shown
to be particularly signiﬁcant in prion pathology (Hetz and Mollereau,
2014; Moreno et al., 2012).
Once translated, proteins are scrutinised for correct folding by
multiple quality control pathways. In the cytosol, the hsp70/hsp40
chaperone system (Kim et al., 2013) surveys proteins for exposed
hydrophobicregionsfoundinmisfoldedproteins. If attemptsat refolding
fail, misfolded proteins are targeted for degradation. For secretory or
membrane proteins which are translocated directly into the endoplas-
mic reticulum (ER) during synthesis (cotranslational translocation),
specialised quality control systems operate within the ER lumen
(ERQC). Here, the situation is more complex than in the cytosol
due to the additional need to monitor signal peptide removal, N-linked
glycosylation, and disulphide bond formation (Braakman and Hebert,
2013). Since the ER lumen lacks degradation machinery, misfolded pro-
teins must be retro-translocated to the cytosol for degradation as part of
the ER-associated degradation (ERAD) pathway. Irreversibly aggregated
ER proteins are subject to ERQC and targeted for lysosomal degradation
via autophagic pathways (Araki and Nagata, 2011). In addition to ERAD
and ERQC pathways, it is likely that protein quality control systems in
other cellular compartments also contribute to the clearance of
misfolded proteins. An important example is the Golgi quality control
(Golgi QC) pathway which directs misfolded proteins from the Golgi di-
rectly to lysosomes for degradation (Anelli and Sitia, 2008; Arvan et al.,
2002).
Misfolded, damaged or aggregated mature proteins are subject to
similar quality control mechanisms as those synthesised de novo
(Hipp et al., 2014). Protein aggregates accumulate in cells when
levels of misfolded proteins overwhelm the quality control systems.
This can arise in conditions of cell stress, mutant protein expression
or prion infection. Different classes of protein inclusions have been
described depending on their cellular location, stability and protein
content. They are thought to play a protective role by sequestering
potentially harmful misfolded proteins from the cellular milieu
(Sontag et al., 2014). Various systems have evolved to deal with
these deposits. Hsp70, Hsp40 and Hsp100 chaperones act in concert
to solubilise aggregates, allowing refolding or degradation (Kim
et al., 2013). Insoluble aggregates are directly targeted for degrada-
tion by binding to adaptor proteins, such as p62 and NBR1 (Bjorkoy
et al., 2005; Kirkin et al., 2009; Pankiv et al., 2007). The eventual
fate of terminally misfolded or aggregated proteins is degradation.
There are two main degradation pathways: the ubiquitin-
proteasome system (UPS) andlysosomal proteolysis (including autoph-
agic pathways). These systems are particularly important in neurons
whose complex architecture, long lifespan and inability to divide (and
thereby dilute the load of damaged proteins), make them particularly
vulnerable to proteotoxic stress.
2. Ubiquitin–proteasome system
As the principal route of protein degradation in mammalian cells,
the UPS represents a major protection against misfolded proteins. Pro-
teins are marked for proteasomal degradation by covalent conjugation
of ubiquitin (Ub) in a sequential reaction involving three enzymes:
ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes
(E2) and ubiquitin ligases (E3) that recognise and transfer ubiquitin to
an internal lysine residue on substrate proteins. In humans, there are
two E1 molecules, a greater diversity of E2s, and several hundred E3s
(Lee et al., 2011). Thus, E3 ubiquitin ligases provide the mechanisms
of substrate speciﬁcity in proteasomal degradation. Following initial
substrate ubiquitination further Ub molecules are added sequentially
to the ﬁrst via one of seven internal lysine residues. In addition to
canonical lysine 48 linkages, lysine 11 and 29 linkages have been
shown to target proteins for proteasomal degradation, with a chain of
four molecules considered the minimum efﬁcient signal (degron) for
recognition by the 26S proteasome (Dantuma and Bott, 2014;
McKinnon and Tabrizi, 2014). This large (2.5 MDa) multi-subunit com-
plex consists of a barrel-shaped 20S catalytic core responsible for proteo-
lytic activity (Groll et al., 2000) and the 19S regulatory particle, which is
important for the recognition, unfolding, and translocation of
ubiquitinated substrates into the 20S core particle (Bedford et al.,
2010). Mutations in different components of the UPS have been identi-
ﬁed in clinical cases of HD, AD and PD (Kitada et al., 1998; van
Leeuwen et al., 2006). Furthermore, experimental knockout of protea-
some subunits in mice has been shown to result in progressive neurode-
generation, clearly demonstrating the importance of proteasome
catalytic activity to neuronal proteostasis and survival (Bedford et al.,
2008; Tashiro et al., 2012). Ageing has also been linked with a reduction
in UPS activity, a factor that may contribute to the late onset of many
neurodegenerative diseases (Gamerdinger et al., 2009; Tydlacka et al.,
2008; Zhou et al., 2003).
Although implicated in the clearance of many disease-associated
proteins (Bhat et al., 2014; Goold et al., 2013; Li et al., 2010),
proteasomaldegradationmayberestrictedtosolublemisfoldedproteins
or smaller oligomeric forms that can be unfolded to allow entry into the
20Scatalyticchamber.Forlarger,moreinsolubleaggregates,thecatalytic
chambermayremaininaccessible,preventingtheireffectivedegradation
(Qin et al., 2003; Scotter et al., 2014). Indeed, many oligomeric and ag-
gregated forms of disease-associated proteins have been shown to inhib-
it proteasome activity, both in reconstituted systems using puriﬁed
c o m p o n e n t s ,a sw e l la si nc u l t u r e dc e l l sa n di nv i v om o d e l s( Andre and
Tabrizi, 2012; Deriziotis et al., 2011; Hong et al., 2014; Kristiansen
et al., 2007). In the context of UPS impairment, an upregulation of au-
tophagy has been described, which may facilitate the clearance of larger
aggregates (Korolchuk et al., 2010). This is a good example of the cross-
talk and close interplay thought to exist between the two degradatory
systems (Hao et al., 2013; Nedelsky et al., 2008).
3. Lysosomal degradation/autophagy
Lysosomesrepresentthemajorcataboliccompartmentineukaryotic
cells. A wide range of enzymatic activities are conﬁned within the
lysosomal limitingmembrane. These include manyclasses of proteolyt-
ic enzymes (Appelqvist et al., 2013). Several routes deliver cell constit-
uents to lysosomes including endolysosomal pathways mediated by
the ESCORT machinery, as well as ERQC and Golgi QC pathways and
autophagic pathways (Saftig and Klumperman, 2009). These systems
are interlinked and crosstalk between them ensures the efﬁcient
removal of obsolete cellular components (Nixon, 2013).
Autophagy is a highly conserved system for the degradation of
cytosolic macromolecules and organelles. Several pathways have been
described with the most important for neuronal proteostasis being
macroautophagy (Jimenez-Sanchez et al., 2012; Nixon, 2013; Yao
et al., 2013). This is a process whereby cytosolic contents are engulfed
in a double membrane-bound structure, called an autophagosome,
which later fuses with lysosomes to enable degradation to take place.
The process begins with formation of a crescent shaped isolation mem-
brane (phagophore). The isolation membrane then extends around a re-
gion of cytoplasm or selected substrate. Subsequent closure of the inner
and outer bilayers of the isolation membrane forms the autophagosome,
w h i c hl a t e rf u s e sw i t hal y s o s o m et oy i e l da na u t o l y s o s o m e( Rubinsztein
et al., 2012) .T h em a m m a l i a nt a r g e tf o rr a p a m y c i nc o m p l e x( m T O R C )i s
an important negative regulator of autophagy whose activity is in-
ﬂuenced by multiple signalling pathways (Rubinsztein et al., 2012).
However, mTORC-independent pathways have also been described
that involve Beclin 1 and the PI3K vps34 (Sarkar et al., 2005; Williams
et al., 2008).
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byamouseconditionalknockoutofatg5,akeyautophagyintermediate,
in the CNS. On atg5 deletion, mice developed behavioural deﬁcits and
neurodegeneration (Hara et al., 2006). Interestingly, affected mice also
accumulated abnormal ubiquitinated proteins which led to the forma-
tionofaggregatesinneurons(Haraetal.,2006).Inductionofautophagy
has been shown to be beneﬁcial in many models of neurodegenerative
disease through the degradation of aggregation-prone mutant proteins
includingHuntingtin(Ravikumaretal.,2004),α-Synuclein (Webbetal.,
2003), APP (Spilman et al., 2010), Tau (Ozcelik et al., 2013)a n dT D P - 4 3
(Wang et al., 2012).
4. Prion disease and proteostasis
To date, many studies have identiﬁed evidence of proteostasis dys-
regulation in prion disease. Early reports demonstrated the presence
of abnormal levels of ubiquitin and ubiquitinated proteins in diseased
mouse brain tissue (Kenward et al., 1994; Lowe et al., 1992). More re-
cent studies have conﬁrmed the presence of ubiquitin-positive staining
in the form of intracellular inclusions or prominent extracellular puncta
in the brains of diseased animals (Kristiansen et al., 2007). The abnormal
levels of ubiquitinated protein indicate a failure of protein degradation
pathways. Accumulation of proteasomal substrates at later stages of dis-
ease correlate with a decrease in proteasome catalytic activity in brain
extracts from diseased animals (Deriziotis et al., 2011; Kristiansen
et al., 2007). Transgenic mice expressing the UPS reporter Ub
G76V-GFP
showed strong reporter accumulation in the brain regions worst affected
by prion disease, supporting a role for proteasomal impairment in dis-
ease pathogenesis (Kristiansen et al., 2007).
Abnormalities in the lysosomal system have also been observed in
prion diseases. Increases in the number and size of autophagic vacuoles
were reportedin thebrainsof patients affected byprion disease, as well
as in mouse models, suggesting that autophagy may be up-regulated in
prion disease (Boellaard et al., 1991; Liberski et al., 2010; Sikorska et al.,
2004). Consistent with this hypothesis, an increase in p62 expression in
diseased brain was recently reported and may reﬂect attempts to in-
crease the clearance of aggregated proteins by autophagy (Homma
et al., 2014).
In addition to impairments in degradation systems, many studies
have indicated that ER stress is a feature of prion disease in both
human patients and animal models (Hetz et al., 2003), with many
UPR markers upregulated relatively early in disease pathogenesis
(Hetz and Soto, 2006; Moreno et al., 2012; Rane et al., 2008). Moreover,
mechanistic studies have shown that prion infection induces a global
down-regulation of protein translation through chronic eIF2αphosphor-
ylation (Moreno et al., 2012) and ER protein translocation impairment
(Rane et al., 2008). Thus, signs of ER stress appear pre-symptomatically
and have been suggested as important mediators of prion toxicity (Hetz
andSoto,2006).However,thecausalrelationshipbetweentheseobserva-
tions and disease pathogenesis is currently unknown. Misfolded PrP in
the ER could induce ER stress (Hetz and Mollereau, 2014). Alternatively,
the accumulation of PrP in aggresomes may sequester cytosolic compo-
nents leading to proteostatic impairment (Chakrabarti and Hegde, 2009;
Kristiansen et al., 2007). Complicating the picture further is the close rela-
tionship that exists between the UPS, autophagy and ER function
(Dantuma and Bott, 2014; Hetz and Mollereau, 2014). For example,
there is a reciprocal relationship between ER stress and proteasome activ-
ity, such that proteasome inhibition has been shown to induce ER stress
and vice versa (Lee et al., 2003; Menendez-Benito et al., 2005). Hence,
deciphering which, if any of these factors, is causal to disease pathogene-
sis presents a signiﬁcant challenge. Despite this, it is clear that disease
pathogenesis is intimately linked to ongoing PrP
Sc propagation (Aguzzi
and Falsig, 2012) and that lowering PrP
Sc load increases the lifespan of
prion-infected mice (Mallucci et al., 2003; Mallucci et al., 2007). As a
result, prion degradation pathways may represent a viable therapeutic
target for the treatment of prion diseases.
5. Prion degradation pathways
In vivo observations support a role for both the lysosomal system
and the UPS in prion degradation. Several studies have reported that
the majority of intracellular PrP
Sc is found in the endolysosomal system
(Jeffrey et al., 2010 and therein). In prion-infected brain tissue, in-
creased numbers and sizes of late endosomes, lysosomes and autopha-
gic vesicles have been described (Boellaard et al., 1991; Liberski et al.,
2010; Sikorska et al., 2004). Dual-labelling experiments also conﬁrmed
the colocalisation of PrP
Sc with lysosomal markers (DeArmond and
Bajsarowicz, 2010). Interestingly, reports of N-terminal truncation of
PrP suggest that lysosomes play an active role in PrP
Sc degradation
(Jeffrey et al., 2003). In addition to the lysosomal system, we have pre-
viously reported a biochemical association between PrP
Sc, 20S protea-
some subunits and other cytosolic aggresome markers (Hsp70 and
vimentin) in prion-infected mouse brain (Kristiansen et al., 2005).
This is of particular interest since aggresomes are thought to sequester
misfolded proteins and target them for degradation by both the UPS
and autophagy (Dantuma and Bott, 2014; Sontag et al., 2014). Thus,
the two major protein clearance pathways appear to be involved in
prion degradation (Fig. 1).
These in vivo ﬁndings were largely conﬁrmed by in vitro ex-
periments in various neuroblastoma and other cultured cell lines
whichstably propagate prions. The potential for genetic and pharmaco-
logical manipulation of cultured cells has facilitated a more detailed
analysis of PrP
Sc intracellular trafﬁcking and degradation pathways.
PrP
Sc is found on the plasma membrane, in the endolysosomal system,
the endosomal recycling compartment, the trans Golgi network and
Golgi (via retromer mediated retrograde transport), in the autophagic
pathway and in the cytosol (Beranger et al., 2002; Borchelt et al.,
1992; Magalhaes et al., 2005; Marijanovic et al., 2009; Rouvinski et al.,
2014; Veith et al., 2009; Yamasaki et al., 2014). Much of the work on
PrP
Sc intracellular distribution was directed at ﬁnding the site of prion
conversion (i.e., the templated misfoldingof native PrP
C into PrP
Sc). De-
spite useful information provided by these studies, they rarely exam-
ined prion degradation directly. This is important because the PrP
Sc
content of a cell at any instant reﬂects the ﬂuctuating balance between
synthesis(i.e.,newprionconversion)anddegradation.Thewidevariety
of compounds known to down-regulate PrP
Sc levels in cultured cells
with no apparent commonality in their mode of action gives an indica-
tion of thecomplexity of prion metabolism(Trevitt and Collinge, 2006).
Hence, the overall PrP
Sc content of a cell is not solely a reﬂection of its
degradation rate and should not be interpreted as such. The situation
is further complicated by the observation that treatments which block
PrP
Sc degradation often lead to an increase in PrP
C levels (Nunziante
et al., 2011). Higher cellular levels of PrP
C are likely to promote prion
conversionandincreasePrP
Sclevelsindependentofanyblockin itsdeg-
radation (Nishida et al., 2000). The converse is also likely to be true,
whereby agents which reduce levels of PrP
Sc also deplete PrP
C (Goold
et al., 2013; Heiseke et al., 2009). It is therefore necessary to interpret
data regardingtotal PrP
Sclevelswithcautionwhenconsideringpossible
mechanisms of degradation.
Recent work looking directly at the degradation of surface-labelled
PrP
Sc has demonstrated an important role of thelysosome in prion deg-
radation (Goold et al., 2013). Autophagy appears to be the major route
of PrP
Sc delivery to lysosomes, at least in chronically-infected cells
(Heiseke et al., 2010; Yao et al., 2013). Genetic ablation of key autopha-
gic components and pharmacological blockade both increase PrP
Sc
levels (Gooldetal.,2013;Heisekeetal.,2009;Heisekeetal.,2010).Con-
versely, stimulating autophagy has been shown to decrease PrP
Sc load
(Aguib et al., 2009; Heiseke et al., 2010; Homma et al., 2014). Other
non-autophagy dependent routes of lysosomal delivery have also been
proposed. Yamasaki and colleagues suggested that upon prion expo-
sure, N2a cells channel a signiﬁcant proportion of newly endocytosed
PrP
Sc through the endolysosomal pathway for rapid degradation
(Yamasaki et al., 2014). Similar ﬁndings have previously been reported
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pathway has been shown to be important for the clearance of some PrP
genetic mutants and newly synthesised PrP
Sc (Ashok and Hegde, 2009;
Goold et al., 2013).Takentogether, thecomplexityof prion degradation
likely reﬂects differences in the cell types used and forms of misfolded
PrP being studied (e.g., mutant PrP isoforms, newly-formed PrP
Sc and
mature PrP
Sc).
In addition to lysosomal and autophagic degradation pathways, our
recent work suggests that the UPS also plays an important role in PrP
Sc
degradation. In chronically-infected cultured cells, we found that appli-
cation of proteasome inhibitors precipitated a rapid rise in PrP
Sc levels,
with detectable increases as early as three hours post-application
(Goold et al., 2013). Importantly, elevated PrP
Sc levels were not accom-
panied by increased PrP
C expression, suggesting that PrP
Sc degradation
itself was the treatment target. Interestingly, proteasomal inhibition
has been shown to lead to aggresome formation in many cell types
(Kawaguchi et al., 2003). In prion-infected cells these perinuclear
inclusions contain PrP
Sc and other typical aggresome markers in-
cluding Hsp70, proteasome subunits and vimentin, (Kristiansen et al.,
2005). These pharmacologically-induced aggresomes suggest the pres-
ence of cytosolic PrP
Sc in cultured cells (Ben Gedalya et al., 2011; Dron
et al., 2009; Kristiansen et al., 2005). This is an important observation
since proteasomal activity is restricted to the cytosol and nucleus
(McKinnon and Tabrizi, 2014) and PrP
Sc must therefore access one of
these compartments to be considered a direct proteasomal substrate.
As an outer leaﬂet membrane protein, mature PrP would not nor-
mally gain access the cytosol. Since prion conversion occurs after PrP
maturation (Borchelt et al., 1990; Caughey and Raymond, 1991)a tt h e
plasma membrane (Goold et al., 2011), and/or following endocytosis
(Beranger et al., 2002; Borchelt et al., 1992; Caughey et al., 1991;
Marijanovic et al., 2009; Yamasaki et al., 2014), PrP
Sc must traverse
the plasma membrane or an intracellular membrane to gain access to
the cytosol. How and where this process takes place remains unclear,
yet various mechanisms can be envisaged. The build-up of aggregated
PrP
Sc in lysosomes may de-stabilise the membrane, causing membrane
leakage of the lumen contents into the cytosol, an event which has pre-
viously been described for other disease related proteins (e.g. Micsenyi
et al., 2013). Alternatively, PrP
Sc may act as an ERAD substrate, as has
been described for certain PrP mutant forms (Jin et al., 2000; Zanusso
et al., 1999).
Once in the cytosol, PrP
Sc ubiquitination and unfolding are likely pre-
requisites for proteasomal degradation. Although ubiquitin-independent
pathways to proteasomal degradation have been described (Finley,
2009), most substrates require ubiquitination for efﬁcient recognition
(Bhattacharyya et al., 2014). Evidence that PrP can be ubiquitinated has
been hard to come by. In vivo, highly sensitive methods were required
to detect ubiquitinated PrP, which was restricted to larger PrP
Sc ag-
gregates present at late stages of disease (Kang et al., 2004; Kovacs
et al., 2005). Although ubiquitin antibodies stain PrP-enriched ag-
gresomes that form following proteasome inhibition in prion-infected
Fig. 1. PrP
Sc formation, trafﬁcking and degradation. Schematic illustrating PrP
Sc metabolism. PrP
Sc forms at the plasma membrane or shortly after endocytosis in endosomes, the ERC or
lysosomes. Recycling of PrP
Sc to the plasma membrane allows prion propagation. Newly formed PrP
Sc undergoes retrograde transport to the trans Golgi network (TGN) and Golgi
where it is subject to Golgi quality control and trafﬁcked to lysosomes for degradation. More mature forms of PrP
Sc are trafﬁcked to lysosomes via the endolysosomal and autophagic
pathways. PrP
Sc may reach the cytosol through lysosomal rupture or ERAD, and accumulates in aggresomes under conditions of proteasome impairment. Unfolding and ubiquitination
precede proteasomal degradation (UPS pathways shown in red). Aggresomal PrP
Sc and smaller insoluble forms are engulfed by phagophores and degraded by autophagic pathways
(shown in orange).
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tween PrP
Sc and ubiquitin immunostaining in vivo have been reported
(Cammarata and Tabaton, 1992). Hence, PrP
Sc does not seem to be
ubiquitinated to a signiﬁcant degree and its status as a genuine protea-
some substrate remains open to debate. It is possible that most PrP
Sc re-
mains non-ubiquitinated and becomes sequestered in Q-bodies — small,
dynamic protein quality control compartments shown to form under
basal conditions in cultured cells (Escusa-Toret et al., 2013; Sontag et al.,
2014). Q-bodies may coalesce to form aggresomes under conditions
of greater cell stress such as those prevalent during pharmacological
proteasome inhibition or in the later stages of prion disease (Grenier
et al., 2006; Kristiansen et al., 2005). Unfolding and ubiquitination
of the Q-body PrP
Sc population could instigate rapid degradation.
Ubiquitinated PrP
Sc would thus represent only a small proportion
of total PrP
Sc at steady state and could remain below detection
thresholds. In addition to direct degradation, the proteasome may
also regulate PrP
Sc levels indirectly through clearance of PrP
C thereby
reducing the substrate levels for prion synthesis (Yedidia et al., 2001).
DecreasingtherateofPrP
Scsynthesismayallowalternativedegradative
systems to reduce the levels of pre-existing PrP
Sc independent of, or in
conjunction with, direct UPS activity.
Recent studies have highlighted the dynamic nature of PrP
Sc metab-
olism. Signiﬁcant increases in PrP
Sc levels can be induced by a blockade
of degradative activity which lasts only a few hours (Goold et al., 2013).
Similarly, stimulation of these pathways clears prions from cells rapidly
(Ertmer et al., 2004). Early metabolic labelling experiments suggested
that much of the total cellular PrP
Sc content is relatively stable
(Boellaard et al., 1991; Caughey and Raymond, 1991). However,
surface-labelling experiments revealed that PrP
Sc on the plasma
membrane is highly labile (Caughey and Raymond, 1991; Goold et al.,
2013). This suggests that there are two populations of PrP
Sc within the
infected cell: a plasma membrane population (including newly formed
PrP
Sc) which is metabolised rapidly, and a more stable, and possibly
more aggregated, internalised population which comprises the majority
of total cellular PrP
Sc. We found that newly formed PrP
Sc is a substrate
for non-autophagy dependent lysosomal degradation (i.e., the Golgi QC
pathway) (Goold et al., 2013). In contrast, PrP
Sc from chronically-
infected cells is also subject to UPS and autophagy-dependent lysosomal
degradation (Goold et al., 2013; Heiseke et al., 2009; Heiseke et al.,
2010; Yao et al., 2013). This difference in metabolic fates may be due to
differential trafﬁcking of PrP
Sc in cells with established prion propagation
(Yamasaki et al., 2014). Alternatively, it could be explained by maturation
of PrP
Sc i n t oam o r ea g g r e g a t e ds t a t eo ri t sd en o v oa p p e a r a n c ei nt h ec y -
tosolic compartment which, as previously discussed, is a necessary pre-
requisite for UPS-mediated degradation.
Signiﬁcantly,inductionofautophagyhasbeenshowntoreducetotal
cellular PrP
Sc levels rapidly (Ertmer et al., 2004). This indicates that
stimulation of cellular degradation systems is sufﬁcient to overcome
the apparent stability of PrP
Sc levels under steady state conditions
(Ertmer et al., 2004; Goold et al., 2013). It is also interesting to note
that some treatments which have been shown to reduce PrP
Sc load in
cultured cells were also shown to be effective in vivo, both in terms of
ar e d u c t i o ni nP r P
Sc load and clinical outcome (Yao et al., 2013).
6. Therapeutics
Prion diseases are fatal neurodegenerative disorders that include
Creutzfeldt–Jakob disease (CJD), Gerstmann–Straussler–Scheinker syn-
drome, kuru and fatal familial insomnia. To date, no therapeutic or pro-
phylactic regimens exist for these disorders. A variety of therapeutic
strategies have been proposed, with most directed at preventing prion
conversion. One approach is to reduce PrP
C expression or trafﬁcking to
the plasma membrane, reducing its availability for prion conversion
(Gilch et al., 2001; Tilly et al., 2003). Alternatively, chemical chaperones
which stabilise PrP
C structure (Cortez and Sim, 2013) or compounds
which prevent interaction of PrP
C with PrP
Sc could be used to prevent
further protein misfolding (Caughey and Race, 1992; Caughey and
Raymond, 1993; Priola et al., 2000). A novel approach targeting the
UPR has reported clinical improvements in prion-infected mice
(Moreno et al., 2013). This study used GSK2606414, a potent PERK in-
hibitor, to reduce the chronic phosphorylation of eIF2α and reverse
the depression of protein translation that contributes to prion toxicity
(Morenoetal.,2012).Interestingly,clinicalimprovementswereevident
despite little effect on the level of PrP
Sc. Despite these encouragingﬁnd-
ings, prion pathogenesis is likely to be multi-factorial, with many ele-
ments contributing to toxicity (Aguzzi and Falsig, 2012). Hence,
treatments aimed at the primary toxic insult (i.e., prion conversion
and PrP
Sc accumulation) should be effective in treating all aspects
of toxicity. Reducing PrP
Sc load by stimulating cellular degradation
pathways (Fig. 2) could therefore, represent an effective therapeutic
strategy.
Consistent with this hypothesis, several studies have reported that
upregulating PrP
Sc degradation can lead to signiﬁcant clinical beneﬁt.
A series of reports have shown that autophagy induction leads to both
PrP
Sc clearance in cell models and more importantly, increased lifespan
in prion-infected mice (reviewed in Yao et al., 2013). Treatment with
rapamycin was shown to activate autophagy in vitro and delay disease
onset in mice with prion disease (Cortes et al., 2012; Heiseke et al.,
2009). Similar effects were reported using compounds which activate
autophagy through mTORC-independent pathways. In prion-infected
mice, trehalose was shown to delay the appearance of PrP
Sc in the
spleen (Aguib et al., 2009) and lithium was found to increase lifespan
(Heiseke et al., 2009). The relatively modest improvements reported
mayreﬂectthedifﬁcultyinachievingthenecessarydrugconcentrations
in vivo due to poor blood brain barrier penetration, or simply because
the effective concentrations of these drugs are particularly high. It
should also be noted that the correlation between PrP
Sc clearance and
the stimulation of autophagy was based primarily on preliminary
in vitro experiments. It is therefore possible, that the above compounds
achievedbeneﬁcialeffectsthroughmodulationofnon-autophagicpath-
ways (Aghdam and Barger, 2007; Maiese et al., 2013).
Severaldrugs originally used to target unrelated pathways have also
been foundto stimulate autophagy and reduce prion disease severity in
mice.Treatmentofprion-infectedmiceat20dayspost-inoculationwith
FK506, a well-known immunosuppressant drug, resulted in an upregu-
lation of autophagic markers, a reduction in PrP
Sc levels and an exten-
sion in lifespan (Nakagaki et al., 2013). Resveratrol, a phytoalexin
enriched in grapes was shown to activate Sirt1, induce autophagy and
protect against prion-mediated toxicity, both in cell culture (Jeong
et al., 2012; Seo et al., 2012) and in an in vivo C. elegans model (Bizat
et al., 2010). The plant extract sulforaphane was originally found to
act through the Nrf2 pathway to protect against oxidative stress
(Chapple et al., 2012). Recent reports have demonstrated that sulfo-
raphane treatment prevents against prion neurotoxicity in cell culture
models (Lee et al., 2014) and induces autophagy in vivo (Liu et al.,
2014). Interestingly, this drug was also shown to activate the UPS
(Ganetal.,2010;Kwak et al., 2007; Liu et al.,2014), makingit anattrac-
tive anti-prion agent.
Increased lysosomal breakdown of PrP
Sc through autophagy-
independent pathways could represent an alternative therapeutic
avenue. Branched polyamines are a class of compounds with well-
established anti-prion activity in cell culture models (Supattapone
et al., 1999; Supattapone et al., 2001). On administration to prion-
infected mice, they were shown to slow the accumulation of splenic
PrP
Sc following intraperitoneal prion inoculation (Solassol et al., 2004).
These compounds bind PrP directly and are thought to facilitate lyso-
somal degradation of PrP
Sc, possibly by breaking up aggregates in the
acidic lysosomal environment (Supattapone et al., 1999). The tyrosine
kinase inhibitor STI571, originally developed to treat chronic myeloid
leukaemia (Capdeville et al., 2002) has also been shown to have anti-
prion activity. This is likely to be through the inhibition of c-Abl which
in turn induces lysosomal degradation of PrP
Sc through an as yet poorly
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ment at an early phase of peripheral scrapie infection delayed the ap-
pearance of PrP
Sc in the brain stem and spinal cord and slowed the
onset of clinical disease in mice (Yun et al., 2007). Although untested
in vivo, tamoxifen is another widely available pharmaceutical that
may have therapeutic applications in prion disease. Tamoxifen and its
metabolite 4-hydroxytamoxifen were shown to induce the lysosomal
degradation of PrP
Sc in prion-infected cells, possibly by diverting the
trafﬁcking of both PrP and cholesterol to lysosomes (Marzo et al.,
2013). A novel approach to upregulate protein clearance is the use of
lysosomal modulators (Bahr et al., 2012). Whilst untested in prion dis-
ease, these have been shown to increase lysosomal protease expression
and activity,and were found tohave protectiveeffects in mousemodels
of AD (Butler et al., 2011; Viswanathan et al., 2012). Their development
has come from the surprising observation that mild lysosomal protease
inhibitioninducestheexpressionof notonlythespeciﬁc enzymetarget,
but also other unrelated proteases (Bahr et al., 2012). This leads to a
global increase in lysosomal enzyme activity and alleviates protein ac-
cumulation and toxicity in disease models (Viswanathan et al., 2012).
Althoughpotentiallyanattractivetargetforanti-priontherapies,the
UPShassofarprovedintractableasadrugtarget.Todate,onlyonebone
ﬁde activator has become available. This drug, IU1, is a speciﬁci n h i b i t o r
of the 19S proteasome-associated ubiquitin chain trimming enzyme,
Usp14. Inhibition of this enzyme blocks substrate deubiquitination
andenhancesitsdegradation.Increaseddegradationofdiseaseassociat-
ed forms of tau, TDP-43 and ataxin-3 in cell culture models have been
reported (Lee et al., 2010). Although untested in vivo, IU1 highlights
the potential for therapies targeting UPS activity. Manipulations aimed
atincreasingthecatalyticactivityofthe20Sproteasomethroughgenet-
ic upregulation of various subunits or small molecule enhancers have
been reported but their signiﬁcance in vivo may be limited (Dantuma
and Bott, 2014; McKinnon and Tabrizi, 2014). One exception is sulfo-
raphane, which has been shown to stimulate all three proteasome pep-
tidase activities in brain extracts from drug treated mice (Liu et al.,
2014).Inaddition,thelevelsofubiquitinatedproteinsandaUPSreport-
er construct were reduced in the brains of these animals. In vitro, sulfo-
raphane increased mtHtt degradation and protected cells against mtHtt
toxicity; an effect which was abrogated by proteasome inhibition (Liu
et al., 2014). To date, the efﬁcacy of sulforaphane against prion disease
remains untested. Its ability to stimulate both the UPS and autophagy
(Liu et al., 2014) make it an attractive anti-prion agent.
An alternative approach is to augment UPS activity by stimulating
the action or expression of chaperone proteins with small molecule
compounds(DantumaandBott,2014).Chaperonescounteractaggrega-
tion,unfold potentialUPS substratesand presentthem in a form readily
degraded by the proteasome. Protective effects of such molecules have
been reported in animal models of spinal-bulbar muscular atrophy
(SBMA) and amyotrophic lateral sclerosis (ALS) (Kalmar et al., 2012;
Fig.2.TherapeutictargetsinPrP
Scdegradationpathways.MembraneassociatedPrP
Scistrafﬁckedtolysosomesfordegradationthroughendolysosomal,Golgiqualitycontrolorautophagic
pathways. CytosolicPrP
Scdegradation is mediatedby autophagy(orange arrows) and the UPS (red arrows). Reagents known to enhance the activity of these pathways are shown inblue
highlights. Identiﬁed target proteins are indicated (details in the text).
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prion disease models.
7. Perspectives
Although no effective treatment exists for prion diseases, many
pathways have been identiﬁed that could be targeted for therapeu-
tic intervention. Prion degradation pathways can be included in this
group. There is good experimental evidence from in vivo and in vitro
studies that pharmacological induction of lysosomal activity clears
PrP
Sc from neuronal cells and has a protective effect against prion
disease pathogenesis. In particular, the beneﬁts of compounds that
induce autophagy are well documented. It seems likely that re-
agents stimulating the UPS could play a similar role. However,
small molecules capable of doing this in vivo have yet to be fully
characterised and their efﬁcacy in prion disease models remains largely
untested. Although still at the experimental level, approaches targeting
PrP
Sc degradation, in combination with other promising methods, may
provide effective therapeutic and/or prophylactic treatments against
prion diseases.
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